Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Signifor, Signifor LAR
Signifor (pasireotide) is a somatostatin analog used primarily for the treatment of Cushing's disease in patients who are not candidates for or have not responded to pituitary surgery or for whom surgery has not been curative. It functions by binding to somatostatin receptors, particularly subtype 5, which is highly expressed in corticotroph tumors responsible for Cushing's disease. This binding inhibits the secretion of adrenocorticotropic hormone (ACTH), which in turn reduces cortisol levels.
For the treatment of Cushing's disease in patients who are not candidates for or have not responded to pituitary surgery or for whom surgery has not been curative.
Outcome:
Increased risk of QT prolongation
Mechanism:
Both drugs can prolong the QT interval.
Outcome:
Increased midazolam levels
Mechanism:
Pasireotide can inhibit CYP3A4.
Outcome:
No clinically significant interaction expected
Mechanism:
None known.
Most likely new formulation: Temperature-stable subcutaneous injection (2026, 60% confidence)
Based on current usage trends and clinical trial data, there is a 70% likelihood of Signifor maintaining its current FDA approval status for Cushing's disease.
Somatostatin Analog
Cyclohexapeptide